Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,734 across all filing types
Latest filing 2021-06-10 Regulatory Filings
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
110年5月營業收入
Regulatory Filings Classification · 90% confidence The document is a revenue summary report for a specific month and year (民國110年05月, which corresponds to May 2021) provided by a listed company. It contains numerical data on net operating revenue for the current month, the same month last year, and cumulative year-to-date figures, along with percentage changes and explanations for significant changes. The document is short (799 characters) and primarily presents financial summary data without detailed financial statements or comprehensive analysis. It does not appear to be a full annual or interim report, nor an earnings release with key highlights. It is more of a periodic revenue update or financial summary. Given the nature and length, it fits best under the category of Regulatory Filings (RNS), which is a fallback for miscellaneous regulatory announcements and financial data disclosures that do not fit other specific categories.
2021-06-10 Chinese
110年5月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company (美時) providing details about fund lending balances and endorsement guarantees for the current and previous months. It contains tabulated financial data but is very short (619 characters) and does not include comprehensive financial statements or analysis. It appears to be a regulatory disclosure of specific financial information rather than a full report or announcement of a report. There is no indication of it being an annual or interim report, audit report, earnings release, or any other detailed report type. Given the nature and length, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory disclosures that do not fit other categories.
2021-06-10 Chinese
110年05月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders such as directors, managers, and major shareholders. It includes specific data on shares held, increases, decreases, and trust shares for various insiders. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of it being a full financial report, earnings release, or regulatory announcement. The document matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is sufficient and contains substantive data on insider shareholdings and transactions.
2021-06-07 Chinese
110年05月董事會成員及持股
Director's Dealing Classification · 95% confidence The document contains detailed tables listing shareholdings of company insiders, including directors, managers, and major shareholders, with specific numbers of shares held and pledged. It focuses on insider shareholdings and related disclosures. There is no indication of financial statements, earnings data, meeting materials, or legal proceedings. The content aligns with reporting of personal share transactions or holdings by company directors and executives. Therefore, this document fits the category of Director's Dealing (DIRS). The document length is 3518 characters, which is consistent with a detailed insider shareholding report rather than a full financial report or announcement.
2021-06-07 Chinese
係因本公司有價證券於集中交易市場達公布注意交易資訊標 準，故公布相關財務業務等重大訊息，以利投資人區別瞭解
Regulatory Filings Classification · 95% confidence The document is a short announcement from a listed company (1795 美時) disclosing significant financial information due to reaching a threshold for disclosure on the Taiwan Stock Exchange. It provides summary financial data for recent periods but does not contain a full financial report or detailed analysis. It references where to find complete financial information on a public information platform, indicating this is a disclosure notice rather than a full report. The document length is only 1494 characters, which is quite short and fits the pattern of a regulatory announcement rather than a full report. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-05-24 Chinese
本公司依金管會指示停止召開原訂股東常會
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company (1795 美時) stating that it is stopping the originally scheduled Annual General Meeting (AGM) due to regulatory instructions related to pandemic measures. It specifies the original AGM date and mentions that the meeting will be rescheduled within a certain period. The document is brief (579 characters) and does not contain any financial data, detailed reports, or presentations. It is an official regulatory announcement about the postponement of the AGM, not the AGM materials themselves or voting results. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about meeting schedule changes.
2021-05-20 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.